99 related articles for article (PubMed ID: 11363057)
1. Being in a research study.
Kunches L; Sax P
AIDS Clin Care; 1996 Jan; 8(1):5-6. PubMed ID: 11363057
[TBL] [Abstract][Full Text] [Related]
2. Use of historical marker data for assessing treatment effects in phase I/II trials when subject selection is determined by baseline marker level.
Lin HM; Hughes MD
Biometrics; 1995 Sep; 51(3):1053-63. PubMed ID: 7548690
[TBL] [Abstract][Full Text] [Related]
3. [Difficulties with conducting clinical trials in France].
Zannad F; Plétan Y
Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
[TBL] [Abstract][Full Text] [Related]
4. Seeking informed consent to cancer clinical trials: describing current practice.
Brown RF; Butow PN; Ellis P; Boyle F; Tattersall MH
Soc Sci Med; 2004 Jun; 58(12):2445-57. PubMed ID: 15081196
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and understanding among cancer patients consenting to participate in clinical trials.
Bergenmar M; Molin C; Wilking N; Brandberg Y
Eur J Cancer; 2008 Nov; 44(17):2627-33. PubMed ID: 18818068
[TBL] [Abstract][Full Text] [Related]
6. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
Feinberg J; Japour AJ
Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
[TBL] [Abstract][Full Text] [Related]
7. Women in early phase trials: an IRB's deliberations.
Anderson JR; Schonfeld TL; Kelso TK; Prentice ED
IRB; 2003; 25(4):7-11. PubMed ID: 14649248
[No Abstract] [Full Text] [Related]
8. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials and tribulations. Spiraling costs threaten gridlock.
Malakoff D
Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
[No Abstract] [Full Text] [Related]
10. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
11. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection.
Fletcher PS; Shattock RJ
Curr Opin Investig Drugs; 2008 Feb; 9(2):189-200. PubMed ID: 18246522
[TBL] [Abstract][Full Text] [Related]
12. HIV and hep B drug trial enrolling.
Vazquez E
Posit Aware; 1997; 8(5):17. PubMed ID: 11364634
[TBL] [Abstract][Full Text] [Related]
13. Some design issues in trials of microbicides for the prevention of HIV infection.
Fleming TR; Richardson BA
J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
[TBL] [Abstract][Full Text] [Related]
15. Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency.
Halpern SD; Karlawish JH; Casarett D; Berlin JA; Townsend RR; Asch DA
Am Heart J; 2003 Dec; 146(6):985-92. PubMed ID: 14660989
[TBL] [Abstract][Full Text] [Related]
16. Public health. Regulatory challenges in microbicide development.
Coplan PM; Mitchnick M; Rosenberg ZF
Science; 2004 Jun; 304(5679):1911-2. PubMed ID: 15218130
[No Abstract] [Full Text] [Related]
17. Pediatric trial of 141W94, Vertex protease inhibitor.
AIDS Treat News; 1997 Jul; (No 275):3. PubMed ID: 11364466
[TBL] [Abstract][Full Text] [Related]
18. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
19. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.
Anderson BD; Adamson PC; Weiner SL; McCabe MS; Smith MA
J Clin Oncol; 2004 Dec; 22(23):4846-50. PubMed ID: 15570088
[TBL] [Abstract][Full Text] [Related]
20. Phase III trials: specific problems associated with the use of a placebo control group.
Cleophas TJ; Van der Meulen J; Kalmansohn RB
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):47-50. PubMed ID: 9147706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
